Combined inhibition of MEK and Plk1 has synergistic anti-tumor activity in NRAS mutant melanoma

About one third of cancers harbor activating mutations in rat sarcoma viral oncogene homolog (RAS) oncogenes. In melanoma, aberrant neuroblastoma-RAS (NRAS) signaling fuels tumor progression in about 20% of patients. Current therapeutics for NRAS driven malignancies barely impact overall survival. T...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:J Invest Dermatol
Egile Nagusiak: Posch, C, Cholewa, BD, Vujic, I, Sanlorenzo, M, Ma, J, Kim, ST, Kleffel, S, Schatton, T, Rappersberger, K, Gutteridge, R, Ahmad, N, Ortiz/Urda, S
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2015
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4567913/
https://ncbi.nlm.nih.gov/pubmed/26016894
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/jid.2015.198
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak